Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OSR Holdings
Bellevue, Washington, United States
- Ownership
- Private
- Employees
- ~21
- Development stage
- Other
01
Overview
OSR Holdings develops oral DNA-based cancer vaccines (via subsidiary Vaximm) with lead asset VXM01 in Phase 2 for glioblastoma, and design-augmented biologics (via subsidiary Darnatein) including a clinical-stage regenerative biologic DRT-102 for spinal fusion and a preclinical osteoarthritis biologic DRT-101; additional preclinical oral immunotherapies target mesothelin, WT1, CEA and PD-L1.[1][2]
- Therapeutic areas
- OncologyNeurologyRheumatology
- Modalities
- DNA vaccineVaccineBiologicRecombinant proteinProtein
- Industry
- Biotech
02
Partnerships
White Lion GBM Innovation Fund (equity financing and glioblastoma-focused collaboration)[1]BCM Europe AG (tokenization and financing framework)[1]
Beyond the preview
Go deeper on OSR Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSR Holdings.